 |
|
The Metabolic Syndrome, Its Component Risk Factors, and Progression of Coronary Atherosclerosis
Ozgur Bayturan, MD;
E. Murat Tuzcu, MD;
Andrea Lavoie, MD;
Tingfei Hu, MS;
Kathy Wolski, MPH;
Paul Schoenhagen, MD;
Samir Kapadia, MD;
Steven E. Nissen, MD;
Stephen J. Nicholls, MBBS, PhD
Arch Intern Med. 2010;170(5):478-484.
Background The mechanism that confers adverse cardiovascular prognosis in patients with the metabolic syndrome (MetS) remains unclear. We sought to investigate the association of MetS and its component risk factors with progression of coronary atherosclerosis.
Methods We performed a systematic review of 3459 patients who participated in 7 clinical trials that monitored coronary atheroma progression with intravascular ultrasonography. Patients with or without MetS were compared with regard to clinical characteristics, coronary atheroma burden at baseline, and change on serial evaluation. Relationships between plaque progression ( 5% increase in percent atheroma volume [PAV]), MetS, and its component risk factors were investigated.
Results The metabolic syndrome was highly prevalent and was associated with greater progression of PAV (+0.51% ± 0.23% vs +0.23% ± 0.24%; P = .003). Multivariable analysis showed that MetS was associated with a greater likelihood of undergoing progression of PAV (adjusted odds ratio [OR], 1.25; 95% confidence interval [CI], 1.05-1.48; P = .01). When the individual components were used in the model instead of MetS, hypertriglyceridemia (OR, 1.26; 95% CI, 1.06-1.49; P = .008) and a body mass index of 30 or higher (1.18, 1.00-1.40; P = .05) predicted progression of PAV. However, after adjusting for its individual components, MetS was no longer an independent predictor (OR, 1.04; 95% CI, 0.79-1.37; P = .79).
Conclusion Although accelerated disease progression is observed in the setting of MetS, this is owing to the presence of individual component risk factors rather than to the presence of the syndrome itself.
Author Affiliations: Department of Cardiovascular Medicine, Heart & Vascular Institute (Drs Bayturan, Tuzcu, Lavoie, Schoenhagen, Kapadia, Nissen, and Nicholls; Mr Hu; and Ms Wolski), Department of Cell Biology (Dr Nicholls), the Imaging Institute (Dr Schoenhagen), and the Center for Cardiovascular Diagnostics and Prevention (Dr Nicholls), Cleveland Clinic, Cleveland, Ohio.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2010;170(5):402.
FULL TEXT
The Metabolic Syndrome as a Cluster of Risk Factors: Is the Whole Greater Than the Sum of Its Parts?: Comment on "The Metabolic Syndrome, Its Component Risk Factors, and Progression of Coronary Atherosclerosis"
Eric L. Ding, Liesbeth A. Smit, and Frank B. Hu
Arch Intern Med. 2010;170(5):484-485.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Year in Atherothrombosis
Sanz and Fuster
J Am Coll Cardiol 2011;58:779-791.
FULL TEXT
Adiponectin and Lipid Profiles Compared with Insulins in Relation to Early Growth of British South Asian and European Children: The Manchester Children's Growth and Vascular Health Study
Bansal et al.
J. Clin. Endocrinol. Metab. 2011;96:2567-2574.
ABSTRACT
| FULL TEXT
Insights From a Virtual World
Nicholls
J Am Coll Cardiol Intv 2011;4:511-512.
FULL TEXT
Anaesthetic considerations with the metabolic syndrome
Tung
Br J Anaesth 2010;105:i24-i33.
ABSTRACT
| FULL TEXT
The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis
Mottillo et al.
J Am Coll Cardiol 2010;56:1113-1132.
ABSTRACT
| FULL TEXT
Metabolic syndrome: More questions than answers?
Spellman and Chemitiganti
J Am Osteopath Assoc 2010;110:eS18-eS22.
FULL TEXT
|
